Exploring Design & Preclinical Characterization of XB773, a Novel Anti-DLL3 Targeting ADC - 17th World ADC San Diego

Your Flagship Event Driving ADC Innovation, Insights & Connections

Register by Friday, August 7 & Save up to $600

Day

Hour

Minute

Second

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Exploring Design & Preclinical Characterization of XB773, a Novel Anti-DLL3 Targeting ADC

12:00 pm - Wednesday 14th October 2026

Evaluating rationale for targeting DLL3 with an ADC, laying out selective overexpression in SCLC and neuroendocrine cancers
Describing design and development of XB773 highlighting humanized VHH Fc antibody conjugated to Topo1 payload via AJICAP conjugation
Laying out preclinical characterization across in vitro cytotoxicity and internalization and in vivo efficacy in CDX and PDX models

Speakers:

Marlene Hennessy

Marlene Hennessy

Principal Scientist

Exelixis, Inc.